Gilead announces response data from Phase 2 study of idelalisib for previously untreated CLL
Gilead Sciences, Inc. announced results from a Phase 2 study...
15 May 2013 | By Gilead Sciences
Gilead Sciences, Inc. announced results from a Phase 2 study...